Haystack MRD™ prioritizes truncal somatic mutations—those mutations that are present at the initial formation of a tumor, or the trunk of the cancer evolutionary tree.
One of the most critical differentiators among minimal residual disease (MRD) tests is whether they are tumor-informed or whether they are tumor-naive.
The landmark DYNAMIC study is the first prospective, randomized, interventional trial to demonstrate the clinical benefit of MRD testing to guide adjuvant therapy
Haystack MRD™ strikes the right balance of DNA molecules interrogated and number of mutations tracked for optimizing test efficiency and sustainability
Connect with us
Social:
Social:
Social:
Social:
Social:
Social:
Social:
Social:
Social:
Social:
Social:
Social:
Social:
Social:
Social:
Social:
